World Ocular Drug Market to Grow Strongly from 2012 to 2022, According to Visiongain14 May 2012 • by Natalie Aster
What are the commercial prospects for treating eye disorders? How will 20 leading ophthalmic drugs - including Lucentis, Visudyne, Xalatan/Xalacom and Restasis - perform from 2012? What will happen next? What are leading companies doing? What effects will competition have?
The answers to all these questions and many more are available in the new study “Ophthalmic Drugs: World Market Prospects 2012-2022” by Visiongain. The report investigates prescription drugs treating human eye diseases, revealing forecasted sales trends at world market, therapeutic submarket, product and national level to 2022.
Forecasting of five submarkets to 2022, with potential revenues, is also available:
- Glaucoma treatments
- Anti-allergy, anti-inflammatory and anti-infective agents
- Retinal disorder treatments
- Dry eye treatments
- Other medicines.
The report covers the R&D pipeline too, by therapeutic area, assessing trends and outlooks.
Ophthalmic Drugs: World Market Prospects 2012-2022
Published: March, 2012
Price: US$ 2.642,00
Visiongain predicts that the world market for ocular drugs will grow strongly from 2012 to 2022. It will be stimulated by increasing prevalence of eye disorders among aging populations. Some national treatment markets will grow fast; others will expand slowly.
Sustained-release ocular implants, gene therapy and RNA interference technology will influence R&D, as will neuroprotective agents for glaucoma. Pipeline developments have strong potential. In 2012, under-met treatment needs remain.
New products - novel small molecules, generics and biologics - will change the sector. Many commercial opportunities for ophthalmic drugs exist, with high revenues possible to 2022. This report shows and explains.
More information can be found in the report “Ophthalmic Drugs: World Market Prospects 2012-2022” by Visiongain.
To order the report or ask for sample pages contact firstname.lastname@example.org